On August 28, 2020, the positive results from the first pivotal Phase 3 study (evaluating 25 and 50 mg doses) of our investigational dual orexin receptor antagonist, daridorexant, in adult and elderly patients with insomnia, were presented by Dr Thomas Roth at SLEEP 2020.

The Associated Professional Sleep Societies (APSS) event, SLEEP 2020, is the world’s largest meeting devoted entirely to clinical sleep medicine, and sleep and circadian research.

• SLEEP 2020
• Presentation
• Press Release
• Late breaker abstract

Idorsia published its half year financial results 2020 on Thursday July 23, 2020.

• Investor webcast
• Webcast presentation

On July 6, 2020, Idorsia announced positive results in the second Phase 3 study of daridorexant. The study confirms the findings of the first pivotal study, demonstrating efficacy of treatment with daridorexant on objective and subjective sleep parameters and showed positive effects on daytime functioning.

• Investor webcast
• Webcast presentation

In April 2020, Idorsia announced positive results in the first Phase 3 study of daridorexant with improved overall sleep and daytime functioning of patients with insomnia.

• Investor webcast
• Webcast presentation

Idorsia published its full year financial results 2019 on Thursday February 6, 2020.

• Investor webcast
• Investor webcast presentation

Idorsia published its half year financial results 2019 on Tuesday July 23, 2019.

• Investor webcast
• Investor webcast presentation

Idorsia published its full year financial results 2018 on Thursday February 7, 2019.

• Investor webcast
• Investor webcast mp3 audio
• Investor webcast presentation

In June 2018, Idorsia announced that the first patient had been enrolled into PRECISION, a Phase 3 study to investigate the efficacy and safety of aprocitentan for resistant hypertension management in adults.

• Investor webcast
• Investor webcast presentation

In June 2018, Idorsia announced that it is initiating a Phase 3 study, REACT, to investigate the efficacy and safety of clazosentan for the prevention of clinical deterioration due to vasospasm-related delayed cerebral ischemia in patients following an aneurysmal subarachnoid hemorrhage. The company also gave an update on the Japanese registration program and the establishment of Idorsia Pharmaceuticals Japan.

• Investor webcast
• Investor webcast presentation

In May 2018, Idorsia announced that the first patient had been enrolled in a registration study to investigate the effect of lucerastat, as an oral monotherapy, for the treatment of adult patients with genetically confirmed Fabry disease, irrespective of their genetic mutation type.

• Investor webcast
• Investor webcast presentation

The information in these investor webcasts was factually accurate at the time of broadcast. These webcasts remain on the Idorsia website for historical purposes only. Idorsia assumes no responsibility to update the information to reflect subsequent developments. Readers should not rely upon the information in these presentations as current or accurate after their publication dates.